$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
A comprehensive introduction to the clinical application of belumosudil (belumosudil)
2026-02-01 22:25:32
Check Details
Brivaracetam original drug information and market status analysis
2026-02-01 22:25:32
Check Details
The latest news on the launch of obeticholic acid (Obeticholic) in the Chinese market in 2025
2026-02-01 22:25:32
Check Details
Comparative analysis of whether neratinib (neratinib) can replace pyrotinib treatment options
2026-02-01 22:25:32
Check Details
Will Alzheimer's disease recur after discontinuation of donanemab?
2026-02-01 22:25:32
Check Details
Is Vorasidenib suitable for patients with low-grade glioma?
2026-02-01 22:25:32
Check Details
Are common adverse reactions of Seladelpar easy to control and alleviate?
2026-02-01 22:25:32
Check Details
What are the differences in ingredients between generic drugs of Lazertinib and the original drugs?
2026-02-01 22:25:32
Check Details
Is it necessary to continue taking Bortezomib long-term after treatment?
2026-02-01 22:25:32
Check Details
Recommended regimen for combined use of Adalimumab and other drugs
2026-02-01 22:25:32
Check Details
Is Tislelizumab a PD-1 or PD-L1 inhibitor?
2026-02-01 22:25:32
Check Details
How many injections of Ustekinumab are required a year?
2026-02-01 22:25:32
Check Details
1
2
...
1763
1764
1765
1766
1767
1768
1769
...
10239
10240
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Ganaxolone Common Side Effects: Somnolence, Sedation and Safety Notes
2
Baxdrostat: Efficacy and Safety of a Novel Aldosterone Synthase Inhibitor
3
Anamorelin (ADLUMIZ): GHS-R1a Agonist for Cancer Cachexia—Mechanism, Use, and Safety Boundaries
4
Vemurafenib Mechanism and Clinical Indications: BRAF V600E Mutant Melanoma and ECD Treatment
5
Anagrelide Cautions and Contraindications: Allergy, Hepatic, Cardiac and Bleeding Risks
6
FDA Accelerated Approval of Voceryq: First Plasmid DNA Immunotherapy for Adult Recurrent Respiratory Papillomatosis
7
Ribociclib: Mechanism of Action and Approved Uses in Breast Cancer
8
Revumenib: Key Considerations Before and During Treatment
9
Pacritinib in Myelofibrosis: Evidence on Spleen Volume Reduction and Symptom Control
10
Binimetinib + Encorafenib: Dual MEK/BRAF Targeting in BRAF+ Tumors
11
Neratinib Dosing: 240mg Start, Diarrhea Prophylaxis, Hepatic Adjustment
12
Pomalidomide vs Thalidomide: IMiD Generation Gap and MM Use